Xinnate AB

Xinnate AB’s clinical research is centered on epidermolysis bullosa, with attention to the severe skin fragility, chronic blistering, and difficult-to-heal wounds associated with the disease. The funded trial focuses on dystrophic epidermolysis bullosa and junctional epidermolysis bullosa, reflecting interest in inherited blistering disorders that require sustained dermatologic care.

• Wound healing
• Skin barrier repair
• Blistering and erosion management
• Dystrophic epidermolysis bullosa
• Junctional epidermolysis bullosa

The sponsor’s activity in this area is directed toward improving local skin outcomes and addressing the persistent symptom burden of inherited epidermolysis bullosa.